As a group of academicians, we celebrate EGFR 20-year anniversary by writing another paper, 🤣🥰. This material is meant for oncology fellows. Papers that shaped the history of EGFR TKI development | LCTT Dove Medical Press dovepress.com/top-20-egfr-ns…

Timely review on drug tolerant persister (DTP) cells following targeted therapy in oncogene-driven lung cancer by BIDMC Cancer Center Harvard Medical School Susumu Kobayashi and colleagues published at Lung Cancer Journal lungcancerjournal.info/article/S0169-…

🏆We're happy to announce that U.S. News & World Report ranked BIDMC as #18 in the nation for "Best Hospitals for Cancer" for 2024 - 2025! We've made the top 20 list for a second consecutive year. For more information, check out this press release: bit.ly/4cKnkLg #BestHospitals

🫁 Today we recognize #WorldLungCancerDay - #LungCancer is the leading cause of cancer death in the US. Our thoracic oncology program has made great strides to improve screening options, develop novel therapies, and revolutionize care for our patients with lung cancer #lcsm

On Aug. 1st we recognized World Lung Cancer Day and Thoracic Medical Oncology BIDMC every day strives to provide medical oncology care for patients within our multidisciplinary clinic--including our nurse coordinator Danielle McDonald and providers (Drs. Rangachari Deepa Rangachari, MD, FASCO and Costa).

Important work from Thoracic Medical Oncology BIDMC BIDMC Cancer Center DF/HCC Harvard Medical School Susumu Kobayashi using cutting-edge scRNA-seq and spatial transcriptomics to decipher the link between apoptosis and drug-tolerant persister cells in EGFR mutated lung cancers nature.com/articles/s4141…

💡Happening now: Our annual faculty retreat, hosted at the beautiful MIT Endicott House - we welcome our clinical and research scientists to this interactive event to encourage collaborations and celebrate our team’s collective discoveries #CancerResearch

The Thoracic Medical Oncology BIDMC BIDMC Cancer Center DF/HCC Harvard Medical School BIDMC Department of Medicine Susumu Kobayashi Deepa Rangachari, MD, FASCO Hollis Viray MD presenting at the 2024 Cancer Center Faculty Retreat

💡Tune in for grand rounds with Daniel Costa, MD, PhD, MMSC on Thursday, 10/31 Thoracic Medical Oncology BIDMC

How to select between osimertinib or afatinib in PACC (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us from 2020 to 2025 tcr.amegroups.org/article/view/9…

Our team is proud to have presented the BIDMC Cancer Center Cancer Center Grant Rounds focused on EGFR PACC (G719X, S768I, others)-mutations: Personalization & Partnership; organized by the Director of Hematology/Oncology Graduate Medical Education BIDMC Hematology/Oncology Fellowship Deepa Rangachari, MD, FASCO

Another fantastic collaboration between Thoracic Medical Oncology BIDMC and the National Cancer Center Japan! A comprehensive analysis of #EGFR exon 19 mutations in #NSCLC. This is crucial, as these mutations can be missed by PCR. Congratulations, Yuji Uehara, MD and Dr. Hiroki Izumi!

We’re proud to share that BIDMC has been named a 2025–26 Best Hospital by U.S. News & World Report! 🏥 Ranked #3 in MA & Boston, with 19 High Performing ratings across specialties like cancer, cardiology & OB/GYN. Learn more: bidmc.org/about-bidmc/ne…